Associated Papers
Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT.
Sun Q et al.
Circulation. Cardiovascular Imaging, 2025
40755316 (PubMed )
Supplement: circcvim-2024-017915-s03.pdf
Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication.
Lee D et al.
Nature Communications, 2025
39794314 (PubMed )
Supplement: 41467_2024_55691_MOESM8_ESM.xlsx › Fig._1i_1h
Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes.
Nead KT et al.
Blood Advances, 2024
38830141 (PubMed )
Supplement: BLOODA_ADV-2024-012929-mmc1.xlsx › STable_2
Cancer-driving mutations are enriched in genic regions intolerant to germline variation.
Vitsios D et al.
Science Advances, 2022
36026442 (PubMed )
Supplement: sciadv.abo6371_tables_s1_to_s13.zip › sciadv.abo6371_tables_s1_to_s13.xlsx › S4
Systematic Profiling of DNMT3A Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor.
Huang YH et al.
Cancer Discovery, 2022
34429321 (PubMed )
Supplement: cd-21-0560_supplementary_table_1_suppst1.xlsx › Sheet1
Functional Analysis of DNMT3A DNA Methyltransferase Mutations Reported in Patients with Acute Myeloid Leukemia.
Khrabrova DA et al.
Biomolecules, 2019
Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors.
Han M et al.
Frontiers in Oncology, 2019
Functional heterogeneity of genetically defined subclones in acute myeloid leukemia.
Klco JM et al.
Cancer Cell, 2014
Select a paper to view details